Fong Peter 4

What Happened Peter Fong, a director of Rocket Pharmaceuticals (RCKT), was awarded equity on June 18, 2026: 22,862 restricted stock units (RSUs) and a 64,860‑share option/award. Both items are reported at $0.00 on the Form 4 (no cash exchanged on the grant/reporting line). These are grants of compensation equity, not open‑market purchases or sales.

Key Details

• Transaction date: June 18, 2026; Form 4 filed July 6, 2026 (filed later than the typical 2‑business‑day deadline).
• Reported amounts/prices: 22,862 RSUs @ $0.00; 64,860‑share option/award @ $0.00 (per filing).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes: F1 — RSUs convert one‑for‑one to common stock and will vest in full on June 18, 2027. F2 — the 64,860‑share option represents the right to purchase that many shares; all will become fully vested and exercisable on June 18, 2027.
• Filing timeliness: The Form 4 was filed ~18 days after the transaction date, later than the usual 2‑business‑day reporting window.

Context These entries are grants of compensation (RSUs and an option right) that vest in one year; they are not exercises or market sales. For retail investors, award grants typically reflect company compensation policy and are not a direct buy/sell signal. The option has not been exercised and the RSUs have not yet converted to shares—both vesting and any exercise would occur (per the filing) on June 18, 2027. The late filing is administrative information investors may note; it does not by itself indicate trading intent.